Company / Accounts Receivable
Akebia Therapeutics, Inc. Accounts Receivable History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$47.0M
FY2025
5-year range
$34.4M / $50.9M
FY2021-FY2025
Trend
+36.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable returned to growth in FY2025 after 3 years of decline, reaching $47M.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of +11.9%.
Improved from $39M to $47M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 36.8% year-over-year.
- Peak accounts receivable was recorded in FY2021.
- Lowest accounts receivable in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.0M | +36.8% |
| FY2024 | $34.4M | -12.5% |
| FY2023 | $39.3M | -2.5% |
| FY2022 | $40.3M | -20.8% |
| FY2021 | $50.9M | +89.5% |
| FY2020 | $26.9M | -30.9% |
| FY2019 | $38.9M | +133.2% |
| FY2018 | $16.7M | - |
| FY2015 | - | - |
| FY2014 | $48.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026